Evgen Pharma PLC

Chart & Performance

D1W1MN

P/E

—

P/S

725.14

EPS

—

Div Yield, %

—

Shrs. gr., 5y

28.04%

Rev. gr., 5y

Revenues

442k

Net income

-4m

L+48.10%

CFO

-4m

L+59.71%

Profile

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

URL

https://evgen.com/

IPO date

Oct 21, 2015

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03
Income
Revenues	442
Cost of revenue	4,095
Unusual Expense (Income)
NOPBT	(3,653)
NOPBT Margin
Operating Taxes	(963)
Tax Rate
NOPAT	(2,690)
Net income	(4,043) 48.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt	(5,000)
Cash flow
Cash from operating activities	(4,127)
CAPEX	(1,000)
Cash from investing activities	4,617
Cash from financing activities
FCF	(2,549)
Balance
Cash	5,000
Long term investments
Excess cash	4,978
Stockholders' equity	(25,105)
Invested Capital	30,413
ROIC
ROCE
EV
Common stock shares outstanding	274,888
Price
Market cap
EV
EBITDA	(3,640)
EV/EBITDA
Interest	64
Interest/NOPBT